Tomasz Kostrzewski

Tomasz Kostrzewski

Auto-generated profile, based on publicly available information

Tomasz Kostrzewski

CN Bio Innovations Ltd, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
TKTomasz Kostrzewski
Tomasz Kostrzewski
PMPaloma Maraver
Paloma Maraver
LOLarissa Ouro‐Gnao
Larissa Ouro‐Gnao
ALAna Levi
Ana Levi
SSSophie Snow
Sophie Snow
DHDavid Hughes
David Hughes
Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD), which to date has no approved drug treatments. There is an urgent need for better understanding of the genetic and molecular pathways that underlie NAFLD/NASH, and currently available preclinical models, be they in vivo or in vitro, do not fully represent key aspects of the human disease state. We have developed a human in vitro co‐culture NASH model using primary human hepatocytes, Kupffer cells and hepatic stellate cells, which are cultured together as microtissues in a perfused three‐dimensional microphysiological system (MPS). The microtissues were cultured in medium containing free fatty acids for at least 2 weeks, to induce a NASH‐like phenotype. The co‐culture microtissues within the MPS display a NASH‐like phenotype, showing key features of the disease including hepatic fat accumulation, the production of an inflammatory milieu, and the expression of profibrotic markers. Addition of lipopolysaccharide resulted in a more pro‐inflammatory milieu. In the model, obeticholic acid ameliorated the NASH phenotype. Microtissues were formed from both wild‐type and patatin‐like phospholipase domain containing 3 (PNPLA3) I148M mutant hepatic stellate cells. Stellate cells carrying the mutation enhanced the overall disease state of the model and in particular produced a more pro‐inflammatory milieu. Conclusion: The MPS model displays a phenotype akin to advanced NAFLD or NASH and has utility as a tool for exploring mechanisms underlying the disease. Furthermore, we demonstrate that in co‐culture the PNPLA3 I148M mutation alone can cause hepatic stellate cells to enhance the overall NASH disease phenotype.

8 June 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
Michele VaccaMichele Vacca
Michele Vacca
JLJack Leslie
Jack Leslie
SVSamuel Virtue
Samuel Virtue
BLBrian Y. H. Lam
Brian Y. H. Lam
OGOlivier Govaere
Olivier Govaere
AVAntonio Vidal-Puig
Antonio Vidal-Puig

15 September 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
TKTomasz Kostrzewski
Tomasz Kostrzewski
SSSophie Snow
Sophie Snow
ABAnya Lindström Battle
Anya Lindström Battle
SPSamantha Peel
Samantha Peel
ZAZahida Ahmad
Zahida Ahmad
DHDavid Hughes
David Hughes
Non-alcoholic steatohepatitis (NASH) is a common form of chronic liver disease characterised by lipid accumulation, infiltration of immune cells, hepatocellular ballooning, collagen deposition and liver fibrosis. There is a high unmet need to develop treatments for NASH. We have investigated how liver fibrosis and features of advanced clinical disease can be modelled using an in vitro microphysiological system (MPS). The NASH MPS model comprises a co-culture of primary human liver cells, which were cultured in a variety of conditions including+/− excess sugar, fat, exogenous TGFβ or LPS. The transcriptomic, inflammatory and fibrotic phenotype of the model was characterised and compared using a system biology approach to identify conditions that mimic more advanced clinical disease. The transcriptomic profile of the model was shown to closely correlate with the profile of patient samples and the model displayed a quantifiable fibrotic phenotype. The effects of Obeticholic acid and Elafibranor, were evaluated in the model, as wells as the effects of dietary intervention, with all able to significantly reduce inflammatory and fibrosis markers. Overall, we demonstrate how the MPS NASH model can be used to model different aspects of clinical NASH but importantly demonstrate its ability to model advanced disease with a quantifiable fibrosis phenotype.

26 May 2022 in PLOS Biology
Verified
Journal Article
Open access
PDF file
DSDharaminder Singh
Dharaminder Singh
SDSudhir P. Deosarkar
Sudhir P. Deosarkar
ECElaine Cadogan
Elaine Cadogan
VFVikki Flemington
Vikki Flemington
ABAlysha Bray
Alysha Bray
CSClay W. Scott
Clay W. Scott
Test compounds used on in vitro model systems are conventionally delivered to cell culture wells as fixed concentration bolus doses; however, this poorly replicates the pharmacokinetic (PK) concentration changes seen in vivo and reduces the predictive value of the data. Herein, proof-of-concept experiments were performed using a novel microfluidic device, the Microformulator, which allows in vivo like PK profiles to be applied to cells cultured in microtiter plates and facilitates the investigation of the impact of PK on biological responses. We demonstrate the utility of the device in its ability to reproduce in vivo PK profiles of different oncology compounds over multiweek experiments, both as monotherapy and drug combinations, comparing the effects on tumour cell efficacy in vitro with efficacy seen in in vivo xenograft models. In the first example, an ERK1/2 inhibitor was tested using fixed bolus dosing and Microformulator-replicated PK profiles, in 2 cell lines with different in vivo sensitivities. The Microformulator-replicated PK profiles were able to discriminate between cell line sensitivities, unlike the conventional fixed bolus dosing. In a second study, murine in vivo PK profiles of multiple Poly(ADP-Ribose) Polymerase 1/2 (PARP) and DNA-dependent protein kinase (DNA-PK) inhibitor combinations were replicated in a FaDu cell line resulting in a reduction in cell growth in vitro with similar rank ordering to the in vivo xenograft model. Additional PK/efficacy insight into theoretical changes to drug exposure profiles was gained by using the Microformulator to expose FaDu cells to the DNA-PK inhibitor for different target coverage levels and periods of time. We demonstrate that the Microformulator enables incorporating PK exposures into cellular assays to improve in vitro–in vivo translation understanding for early therapeutic insight.

23 July 2025 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
YAYassen Abbas
Yassen Abbas
MWMorné van Wyk
Morné van Wyk
HSHailey Sze
Hailey Sze
JCJames Christophi
James Christophi
ASAshley A. Spreen
Ashley A. Spreen
TKTomasz Kostrzewski
Tomasz Kostrzewski
Oral bioavailability is a crucial pharmacokinetic (PK) parameter optimized by drug developers working on new therapeutic compounds. The goal is to obtain adequate systemic exposure and to establish safe and effective therapeutic dosages. Critical to optimizing oral bioavailability is understanding a compound's susceptibility to first-pass metabolism, determined by the intricate relationship between gut absorption, metabolism, and hepatic metabolism. Efforts to model this relationship in vitro have led to the emergence of microphysiological systems (MPSs) that consist of multiple, fluidically linked organs. Here, we describe an MPS that links the gut and liver, capable of simulating both oral and intravenous dosing routes and is made up of entirely primary human cells: a gut barrier tissue comprised of an intestinal epithelial monolayer derived from the human jejunum, and a liver microtissue, derived from primary human hepatocytes. Functionality of gut and liver tissues is maintained in coculture enabling the PK investigation of oral compounds. We combine the primary Gut/Liver MPS with a mechanistic mathematical model to generate organ-specific PK parameters and estimate human oral bioavailability and its components: the fraction absorbed (Fa), the fraction escaping gut wall elimination (Fg), and the fraction escaping hepatic elimination (Fh). We used the CYP3A-mediated compound midazolam, which is subjected to both intestinal and hepatic extraction, to demonstrate the transformative potential of the primary Gut/Liver MPS to mechanistically model the PKs of oral compounds in vitro. SIGNIFICANCE STATEMENT: Bioavailability underpins the success or when insufficient, can stall the development of oral therapeutics. The drug discovery process lacks in vitro assays that can profile the contribution to bioavailability by the gut and liver. The primary Gut/Liver MPS outlined in this study bridges this gap.

1 May 2021 in Alternatives to Laboratory Animals
Verified
Journal Article
Closed access
PDF file
BSBhumika Singh
Bhumika Singh
MAMohamed Abdelgawad
Mohamed Abdelgawad
ZAZulfiqur Ali
Zulfiqur Ali
JBJarrod Bailey
Jarrod Bailey
EBElisa Budyn
Elisa Budyn
JWJohn Malcolm Wilkinson
John Malcolm Wilkinson
Experimental systems that faithfully replicate human physiology at cellular, tissue and organ level are crucial to the development of efficacious and safe therapies with high success rates and low cost. The development of such systems is challenging and requires skills, expertise and inputs from a diverse range of experts, such as biologists, physicists, engineers, clinicians and regulatory bodies. Kirkstall Limited, a biotechnology company based in York, UK, organised the annual conference, Advances in Cell and Tissue Culture (ACTC), which brought together people having a variety of expertise and interests, to present and discuss the latest developments in the field of cell and tissue culture and in vitro modelling. The conference has also been influential in engaging animal welfare organisations in the promotion of research, collaborative projects and funding opportunities. This report describes the proceedings of the latest ACTC conference, which was held virtually on 30th September and 1st October 2020, and included sessions on in vitro models in the following areas: advanced skin and respiratory models, neurological disease, cancer research, advanced models including 3-D, fluid flow and co-cultures, diabetes and other age-related disorders, and animal-free research. The roundtable session on the second day was very interactive and drew huge interest, with intriguing discussion taking place among all participants on the theme of replacement of animal models of disease.